Last reviewed · How we verify
Ibrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged ≤65 Years
The purpose of the study is to better and systematically collect clinical data on the treatment of ibrutinib combined with R-CHOP/DHAP regimen for more scientific and accurate evaluation, our center has carried out the R-CHOP/R-DHAP alternative regimen combined with ibrutinib at age ≤ An observational clinical study on the safety and effectiveness of 65-year-old mantle cell lymphoma. Through this study, young mantle cell lymphomas in the Chinese population can be collected. Ibrutinib combined with R-CHOP/R-DHAP is used in the initial treatment. 2 and 6 cycles of ORR were used to evaluate survival indicators, and collect adverse reactions during treatment and recurrence rate after treatment.
Details
| Lead sponsor | Peking University Third Hospital |
|---|---|
| Status | UNKNOWN |
| Enrolment | 60 |
| Start date | Wed Dec 30 2020 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Sun Jun 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Mantle Cell Lymphoma
Countries
China